JP2019088286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019088286A5 JP2019088286A5 JP2018243703A JP2018243703A JP2019088286A5 JP 2019088286 A5 JP2019088286 A5 JP 2019088286A5 JP 2018243703 A JP2018243703 A JP 2018243703A JP 2018243703 A JP2018243703 A JP 2018243703A JP 2019088286 A5 JP2019088286 A5 JP 2019088286A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ala
- seq
- ile
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020114090A JP6923714B2 (ja) | 2012-09-14 | 2020-07-01 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261701056P | 2012-09-14 | 2012-09-14 | |
| US61/701,056 | 2012-09-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532065A Division JP6461796B2 (ja) | 2012-09-14 | 2013-09-13 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114090A Division JP6923714B2 (ja) | 2012-09-14 | 2020-07-01 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019088286A JP2019088286A (ja) | 2019-06-13 |
| JP2019088286A5 true JP2019088286A5 (enExample) | 2019-10-24 |
| JP6728326B2 JP6728326B2 (ja) | 2020-07-22 |
Family
ID=49253425
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532065A Active JP6461796B2 (ja) | 2012-09-14 | 2013-09-13 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
| JP2018243703A Active JP6728326B2 (ja) | 2012-09-14 | 2018-12-26 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
| JP2020114090A Active JP6923714B2 (ja) | 2012-09-14 | 2020-07-01 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
| JP2021124003A Active JP7270001B2 (ja) | 2012-09-14 | 2021-07-29 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ－ａ３を認識するｔ細胞受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532065A Active JP6461796B2 (ja) | 2012-09-14 | 2013-09-13 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114090A Active JP6923714B2 (ja) | 2012-09-14 | 2020-07-01 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
| JP2021124003A Active JP7270001B2 (ja) | 2012-09-14 | 2021-07-29 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ－ａ３を認識するｔ細胞受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9879065B2 (enExample) |
| EP (3) | EP2895509B1 (enExample) |
| JP (4) | JP6461796B2 (enExample) |
| KR (4) | KR102165350B1 (enExample) |
| CN (2) | CN104968675B (enExample) |
| AU (4) | AU2013315391B2 (enExample) |
| CA (1) | CA2884743C (enExample) |
| CY (1) | CY1122720T1 (enExample) |
| DK (2) | DK2895509T3 (enExample) |
| ES (2) | ES2925307T3 (enExample) |
| HR (1) | HRP20200325T1 (enExample) |
| HU (1) | HUE048014T2 (enExample) |
| IL (3) | IL286786B (enExample) |
| LT (1) | LT2895509T (enExample) |
| MX (2) | MX367279B (enExample) |
| PL (1) | PL2895509T3 (enExample) |
| PT (1) | PT2895509T (enExample) |
| SI (1) | SI2895509T1 (enExample) |
| SM (1) | SMT202000103T1 (enExample) |
| WO (1) | WO2014043441A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9879065B2 (en) * | 2012-09-14 | 2018-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| ES2924709T3 (es) * | 2014-10-02 | 2022-10-10 | Us Health | Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer |
| CN107075479A (zh) | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞的方法 |
| IL301919A (en) * | 2015-03-27 | 2023-06-01 | Immatics Biotechnologies Gmbh | Innovative peptides and a combination of peptides for use in immunotherapy against various tumors |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| WO2017070042A1 (en) | 2015-10-20 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t cell populations using akt inhibitors |
| WO2017139199A1 (en) | 2016-02-10 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible arginase |
| EP3416668A4 (en) * | 2016-02-18 | 2020-02-19 | The Wistar Institute Of Anatomy And Biology | METHOD AND COMPOSITIONS FOR TREATING MELANOMA |
| GB201604494D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| HRP20221375T1 (hr) * | 2016-03-16 | 2023-01-06 | Immatics Biotechnologies Gmbh | Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| CN106749620B (zh) * | 2016-03-29 | 2020-09-25 | 广东香雪精准医疗技术有限公司 | 识别mage-a1抗原短肽的t细胞受体 |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| EP4166161B1 (en) | 2016-04-14 | 2026-03-04 | Fred Hutchinson Cancer Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| WO2018097951A1 (en) | 2016-11-22 | 2018-05-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3/a6 antibodies |
| DE102016123859B3 (de) | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| CN108250289B (zh) * | 2016-12-28 | 2021-10-08 | 香雪生命科学技术（广东）有限公司 | 源自于mage b6的肿瘤抗原短肽 |
| WO2018129270A1 (en) | 2017-01-05 | 2018-07-12 | Fred Hutchinson Cancer Research Center | Systems and methods to improve vaccine efficacy |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| US12227554B2 (en) * | 2017-10-05 | 2025-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selectively expanding cells expressing a TCR with a murine constant region |
| WO2019075055A1 (en) | 2017-10-11 | 2019-04-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS |
| CN109776671B (zh) * | 2017-11-14 | 2022-05-27 | 杭州康万达医药科技有限公司 | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 |
| CN109836490A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向mage-a3的t细胞受体、t细胞受体基因修饰t细胞及其制备方法和应用 |
| CN109837248A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种tcr敲除的靶向mage-a3的t细胞受体基因修饰t细胞及其制备方法和应用 |
| WO2019143948A1 (en) | 2018-01-18 | 2019-07-25 | Fred Hutchinson Cancer Research Center | Altering inflammatory states of immune cells in vivo by modulating cellular activation states |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| AU2019218729B2 (en) | 2018-02-06 | 2025-12-04 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors |
| ES3052818T3 (en) | 2018-02-09 | 2026-01-14 | Us Health | Tethered interleukin-15 and interleukin-21 |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| KR102892744B1 (ko) | 2018-04-19 | 2025-11-28 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Mage-b2 특이성을 갖는 t 세포 수용체 및 이의 용도 |
| CN112262212B (zh) | 2018-04-24 | 2024-07-12 | 美国卫生和人力服务部 | 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 |
| EP3714941A1 (en) * | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| MA55911A (fr) | 2019-05-08 | 2022-03-16 | 2Seventy Bio Inc | Lymphocytes t génétiquement modifiés |
| US20210040558A1 (en) * | 2019-07-15 | 2021-02-11 | Neogene Therapeutics B.V. | Method to isolate tcr genes |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| IL295063A (en) | 2020-02-04 | 2022-09-01 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Chimeric antigen receptors (car) against dinitrophenol |
| JP2020143057A (ja) * | 2020-04-01 | 2020-09-10 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 |
| EP4211228B1 (en) | 2020-09-08 | 2025-11-05 | The United States of America, as represented by the Secretary, Department of Health and Human Services | T cell phenotypes associated with response to adoptive cell therapy |
| EP4243937A2 (en) | 2020-11-13 | 2023-09-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
| CA3202874A1 (en) | 2020-12-22 | 2022-06-30 | Carsten LINNEMANN | Peptide markers to track genetically engineered cells |
| US20250057949A1 (en) | 2021-12-31 | 2025-02-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | T cell therapy with vaccination as a combination immunotherapy against cancer |
| CN117986350B (zh) * | 2023-02-23 | 2024-08-16 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| AU2025212850A1 (en) | 2024-01-26 | 2026-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1 |
| WO2025250587A1 (en) | 2024-05-29 | 2025-12-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Drug-regulatable, inducible cytokine expression |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| JP2013535199A (ja) * | 2010-07-28 | 2013-09-12 | イムノコア リミテッド | Ｔ細胞レセプター |
| ES2635335T3 (es) * | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| WO2012054825A1 (en) | 2010-10-22 | 2012-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3 t cell receptors and related materials and methods of use |
| CN102251033B (zh) * | 2011-07-05 | 2013-03-20 | 北京大学人民医院 | 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒 |
| SI2755997T1 (sl) | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
| US9413985B2 (en) * | 2012-09-12 | 2016-08-09 | Lattice Semiconductor Corporation | Combining video and audio streams utilizing pixel repetition bandwidth |
| US9879065B2 (en) * | 2012-09-14 | 2018-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
-
2013
- 2013-09-13 US US14/427,671 patent/US9879065B2/en active Active
- 2013-09-13 IL IL286786A patent/IL286786B/en unknown
- 2013-09-13 CA CA2884743A patent/CA2884743C/en active Active
- 2013-09-13 ES ES19212016T patent/ES2925307T3/es active Active
- 2013-09-13 DK DK13767200.2T patent/DK2895509T3/da active
- 2013-09-13 SM SM20200103T patent/SMT202000103T1/it unknown
- 2013-09-13 HR HRP20200325TT patent/HRP20200325T1/hr unknown
- 2013-09-13 EP EP13767200.2A patent/EP2895509B1/en active Active
- 2013-09-13 KR KR1020157006543A patent/KR102165350B1/ko active Active
- 2013-09-13 JP JP2015532065A patent/JP6461796B2/ja active Active
- 2013-09-13 DK DK19212016.0T patent/DK3636665T3/da active
- 2013-09-13 HU HUE13767200A patent/HUE048014T2/hu unknown
- 2013-09-13 PL PL13767200T patent/PL2895509T3/pl unknown
- 2013-09-13 EP EP22174521.9A patent/EP4159753A1/en active Pending
- 2013-09-13 KR KR1020217029207A patent/KR102370307B1/ko active Active
- 2013-09-13 SI SI201331678T patent/SI2895509T1/sl unknown
- 2013-09-13 KR KR1020227006700A patent/KR102480188B1/ko active Active
- 2013-09-13 CN CN201380059102.4A patent/CN104968675B/zh active Active
- 2013-09-13 WO PCT/US2013/059608 patent/WO2014043441A1/en not_active Ceased
- 2013-09-13 KR KR1020207028713A patent/KR102303166B1/ko active Active
- 2013-09-13 LT LTEP13767200.2T patent/LT2895509T/lt unknown
- 2013-09-13 MX MX2015003061A patent/MX367279B/es active IP Right Grant
- 2013-09-13 AU AU2013315391A patent/AU2013315391B2/en active Active
- 2013-09-13 PT PT137672002T patent/PT2895509T/pt unknown
- 2013-09-13 CN CN202111028896.0A patent/CN113754755A/zh active Pending
- 2013-09-13 ES ES13767200T patent/ES2774931T3/es active Active
- 2013-09-13 EP EP19212016.0A patent/EP3636665B1/en active Active
-
2015
- 2015-03-04 IL IL237560A patent/IL237560B/en active IP Right Grant
- 2015-03-10 MX MX2019009641A patent/MX2019009641A/es unknown
-
2017
- 2017-08-23 AU AU2017219019A patent/AU2017219019B2/en active Active
- 2017-12-20 US US15/848,344 patent/US10611815B2/en active Active
-
2018
- 2018-12-26 JP JP2018243703A patent/JP6728326B2/ja active Active
-
2019
- 2019-08-06 AU AU2019213329A patent/AU2019213329B2/en active Active
-
2020
- 2020-03-03 CY CY20201100190T patent/CY1122720T1/el unknown
- 2020-03-09 US US16/812,845 patent/US20200270329A1/en not_active Abandoned
- 2020-04-16 IL IL274003A patent/IL274003B/en unknown
- 2020-07-01 JP JP2020114090A patent/JP6923714B2/ja active Active
-
2021
- 2021-06-07 AU AU2021203746A patent/AU2021203746B2/en active Active
- 2021-07-29 JP JP2021124003A patent/JP7270001B2/ja active Active
-
2022
- 2022-09-28 US US17/936,006 patent/US12404317B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528061A5 (enExample) | ||
| JP2022533796A5 (enExample) | ||
| ES2784237T3 (es) | Receptores de células T anti-papilomavirus 16 E7 humano | |
| JP2026021299A5 (enExample) | ||
| JP6928380B2 (ja) | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス | |
| Yoo et al. | Oncolytic virus‐based immunotherapies for hepatocellular carcinoma | |
| HRP20200383T1 (hr) | Ciljana vezna sredstva protiv b7-h1 | |
| CN113382745A (zh) | 用DuoCAR治疗癌症的组合物和方法 | |
| JP2018536431A5 (enExample) | ||
| JP7438552B2 (ja) | 注射用医薬品、注射用調製物、および注射用医薬品の製造における使用 | |
| CN108473950A (zh) | 靶向癌症治疗 | |
| JP2017186337A5 (enExample) | ||
| CN102459344A (zh) | 抗axl抗体 | |
| TW202108181A (zh) | 抗trop2抗體及其生產方法、及抗trop2抗體-藥物結合物 | |
| JP2024059656A (ja) | コード化リボ核酸の器官保護発現および調節のための組成物および方法 | |
| CN104710337B (zh) | 异硫氰酸酯类化合物及其应用 | |
| US20220267770A1 (en) | Compositions and methods of using c/ebp alpha sarna | |
| JP2022551486A (ja) | イヌジステンパーウイルスのヘマグルチニンおよび融合ポリペプチド | |
| JP2019500907A (ja) | 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法 | |
| JP2020529395A5 (enExample) | ||
| Fallah et al. | A gene-based anti-angiogenesis therapy as a novel strategy for cancer treatment | |
| JP2008500277A5 (enExample) | ||
| Nakamura et al. | Anti-patched-1 antibodies suppress hedgehog signaling pathway and pancreatic cancer proliferation | |
| JP2020526202A5 (enExample) | ||
| JP2018537433A5 (enExample) |